Magnitude of Benefit and Costs for Recent Solid Tumor Agents von Binder, G, Milentijevic, D, Squier, M, Whiting, S, Brown, G, Renschler, M.F

Volltext

Budget Impact of Albumin-Bound Paclitaxel + Gemcitabine in the Treatment of Metastatic Pancreatic Cancer von Binder, G, Whiting, S, Milentijevic, D, Penenberg, D, Wei, X, Kayitalire, L, Renschler, M.F

Volltext

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer von Socinski, M.A., Langer, C.J., Okamoto, I., Hon, J.K., Hirsh, V., Dakhil, S.R., Page, R.D., Orsini, J., Zhang, H., Renschler, M.F.

Volltext

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma von Hersh, E.M., Del Vecchio, M., Brown, M.P., Kefford, R., Loquai, C., Testori, A., Bhatia, S., Gutzmer, R., Conry, R., Haydon, A., Robert, C., Ernst, S., Homsi, J., Grob, J.J., Kendra, K., Agarwala, S.S., Li, M., Clawson, A., Brachmann, C., Karnoub, M., Elias, I., Renschler, M.F., Hauschild, A.

Volltext

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer von Socinski, M.A., Okamoto, I., Hon, J.K., Hirsh, V., Dakhil, S.R., Page, R.D., Orsini, J., Yamamoto, N., Zhang, H., Renschler, M.F.

Volltext

Motexafin Gadolinium (MGd) is Active as a Single Agent and in Combination with Pemetrexed and Docetaxel in Advanced Non–Small-Cell Lung Cancer (NSCLC) Patients who Failed Platinum-... von Natale, R.B, Nicholas, G, Pandya, K, Edelman, M, Phan, S.C, Renschler, M.F

Volltext

PCN11 - Magnitude of Benefit and Costs for Recent Solid Tumor Agents von Binder, G., Milentijevic, D., Squier, M., Whiting, S., Brown, G., Renschler, M.F.

Volltext

PCN40 - Budget Impact of Albumin-Bound Paclitaxel + Gemcitabine in the Treatment of Metastatic Pancreatic Cancer von Binder, G., Whiting, S., Milentijevic, D., Penenberg, D., Wei, X., Kayitalire, L., Renschler, M.F.

Volltext

41 von Mehta, M.P., Carrie, C., Mahe, M.A., Roa, W., Nieder, C., Ung, Y., Eble, M., Phan, S.C., Smith, J.A., Renschler, M.F.

Volltext

1110 von Suh, J.H., Mehta, M.P., Dagnault, A., Chabot, P., Chang, E.L., Fortin, M.A., Grecula, J.C., Nabid, A., Souhami, L., Renschler, M.F.

Volltext

1110: Motexafin Gadolinium-Based Treatment Planning MRI Identifies Occult Brain Metastases Amenable to Stereotactic Radiosurgery: Imaging Results of a Phase II Trial of Motexafin G... von Suh, J.H., Mehta, M.P., Dagnault, A., Chabot, P., Chang, E.L., Fortin, M.A., Grecula, J.C., Nabid, A., Souhami, L., Renschler, M.F.

Volltext

41: Motexafin Gadolinium (MGd) Combined With Prompt Whole Brain Radiation Therapy Prolongs Time to Neurologic Progression in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain... von Mehta, M.P., Carrie, C., Mahe, M.A., Roa, W., Nieder, C., Ung, Y., Eble, M., Phan, S.C., Smith, J.A., Renschler, M.F.

Volltext

Motexafin gadolinium (MGd) overcomes adverse survival effect of anemia in brain metastases (BM) patients treated with whole brain radiation therapy (WBRT): analysis of a phase III... von Kumar, P, Mehta, M.P, Rodrigus, P, Suh, J, Sagar, S, Kunkler, I, Carrie, C, Smith, J.A, Phan, S, Renschler, M.F

Volltext

Predictors of survival for patients with brain metastases: results of a randomized phase III trial von Curran, W.J, Mehta, M, Rodrigus, P, Terhaard, C, Rao, A, Suh, J, Roa, W, Souhami, L, Bezjak, A, Leibenhaut, M, Komaki, R, Schultz, C, Timmerman, R, Illidge, T, Phan, S, Smith, J, DeVault, A, Miller, R, Renschler, M.F

Volltext

Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium von Mehta, M.P., Rodrigus, P., Terhaard, C.H., Rao, A., Suh, J., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M., Komaki, R., Schultz, C.J., Timmerman, R., Illidge, T., Meyers, C.A., Curran, W.J., Phan, S.C., Smith, J., Renschler, M.F.

Volltext

Most troublesome quality of life concerns in patients with brain metastases: baseline results from the phase III trial with motexafin gadolinium von Rodrigus, P., Mehta, M.P., Dehnad, H., Rao, A., Suh, J., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M., Komaki, R., Schultz, C.J., Timmerman, R., Illidge, T., Curran, W.J., Phan, S.C., Smith, J., Renschler, M.F.

Volltext

Motexafin gadolinium prolongs time to neurologic progression in lung cancer patients with brain metastases: results of a randomized phase III trial von Mehta, M., Rodrigus, P., Terhaard, C., Rao, A., Suh, J., Roa, W., Shapiro, W., Glantz, M., Patchell, R., Weitzner, M., Souhami, L., Bezjak, A., Leibenhaut, M., Komaki, R., Schultz, C., Timmerman, R., Illidge, T., Meyers, C., Curran, W., Phan, S., Smith, J., Miller, R.A., Renschler, M.F.

Volltext

XCYTRIN ™ (motexafin gadolinium) and whole brain radiation for patients with brain metastases: Lead-in phase to randomized trial - final results von Mehta, M.P, Meyers, C.A, Curran, W.J, Schultz, C.J, Ford, J.M, Roa, W.H, Leibenhaut, M, Cmelak, A.J, Rao, A, Timmerman, R.D, Gaspar, L, Phan, S.C, Eber, D, Renschler, M.F

Volltext

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer... von Yardley, D.A, Brufsky, A, Coleman, R.E, Conte, P.F, Cortes, J, Glueck, S, Nabholtz, J-M.A, O'Shaughnessy, J, Beck, R.M, Ko, A, Renschler, M.F, Barton, D, Harbeck, N

Volltext bestellen

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer... von Yardley, D.A, Brufsky, A, Coleman, R.E, Conte, P.F, Cortes, J, Glueck, S, Nabholtz, J.-M.A, O'Shaughnessy, J, Beck, R.M, Ko, A, Renschler, M.F, Barton, D, Harbeck, N

Volltext bestellen